Ross Soo

14PUBLICATIONS
90CO-AUTHORS
Predictive and prognostic markersCancer diagnosisMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical biotechnology diagnostics (incl. biosensors)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jun 01, 2025
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab.

Zofia Piotrowska, Antonio Passaro, Danny Nguyen

|May 09, 2025
Early Lung Cancer Patient Journey in Singapore: Challenges and Recommendations.

Lynette Teo, Mariko Siyue Koh, Kevin Lee Min Chua

|Mar 21, 2025
Will "Sun"-WUKONG, the monkey king, conquer EGFR exon 20 insertion mutation positive non-small cell lung cancer?

Molly Li, Ross A Soo

|Sep 25, 2024
HER3 is widely expressed across diverse subtypes of NSCLC in a retrospective analysis of archived tissue samples.

Ross A Soo, Graham Clinthorne, Anu Santhanagopal

|Sep 09, 2024
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.

Ross A Soo, Urania Dafni, Ji-Youn Han

|May 31, 2024
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.

Benjamin J Solomon, Geoffrey Liu, Enriqueta Felip

Pageof 3

Frequent Collaborators

4 joint publications

James Chih-Hsin Yang

3 joint publications

Yi-Long Wu

3 joint publications

Shun Lu

3 joint publications

Dong-Wan Kim